Top 5 Stocks to Buy According to Patrick Degorce’s Theleme Partners

1. Moderna, Inc. (NASDAQ:MRNA)

Degorce’s Stake Value: $1,426,811,000
Percentage of Patrick Degorce’s 13F Portfolio: 41.65%
Number of Hedge Fund Holders: 37

Moderna, Inc. (NASDAQ:MRNA) is placed first on the list of top 9 stocks to buy according to Patrick Degorce’s Theleme Partners.

On October 7, Moderna (NASDAQ:MRNA) announced its plans to build a cutting-edge mRNA plant in Africa to manufacture up to 500 million vaccine doses at a 50g dosage level per year. The company intends to invest up to $500 million in this new plant. In August, Oppenheimer analyst Hartaj Singh downgraded Moderna, Inc. (NASDAQ:MRNA) to “Perform” from “Outperform.” According to Singh, Moderna’s non-Covid pipeline is still 2-3 years away from commercialization, and Covid vaccines will face financial pressure as soon as 2023.

In its second-quarter 2021 investor letter, Carillon Tower Advisers, an investment management firm, mentioned Moderna, Inc. (NASDAQ:MRNA). Here is what the fund said:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock outperformed in the quarter, as the firm’s COVID-19 vaccine has shown effectiveness against the emerging variants of the disease, specifically the now prevalent Delta variant. The potential need for additional booster shots of the vaccine to maintain longer-term immunity as well as protection against possible future variants is also contributing to the stock’s move higher.”

You can also take a peek at 10 Best Healthcare Stocks to Buy According to Matthew Halbower’s Pentwater Capital Management and 10 Large-Cap Stocks to Buy According to Anand Parekh’s Alyeska Investment Group